The Clinical Significance of Metabolic Syndrome in Hypertension: Metabolic Syndrome Increases Cardiovascular Risk

The Pro Position
Current Opinion


Changes in lifestyle in the developed world are promoting the epidemic growth of overweight and obesity, leading to several metabolic abnormalities (lipids, glucose and blood pressure), and increasing the future risk of type 2 diabetes mellitus, cardiovascular events and death. Metabolic syndrome represents the combination of abdominal obesity, insulin resistance, atherogenic dyslipidaemia, and prothrombotic and proinflammatory states. Although some controversies in the pathogenesis and clinical importance of metabolic syndrome still remain, the development of useful clinical tools to identify these patients more easily has enabled an increased recognition in the adult population. Management of patients with metabolic syndrome is a clinical challenge and requires a multifactorial, multidisciplinary approach. Changes in lifestyle are obviously the first therapeutic step and include both dietary modifications and increased daily exercise. Several questions remain to be elucidated with respect to pharmacological treatment. The blood pressure levels required to initiate antihypertensive treatment, the blood pressure goal to be achieved and the possibility of including a renin-angiotensin system blocker as a part of the pharmacological treatment are still under discussion. Moreover, there is either a lack of or poor evidence on the need for specific drugs to reduce triglycerides, to increase high-density lipoprotein-cholesterol, to improve insulin sensitivity or to decrease abdominal obesity. Independently, it is generally accepted that earlier and more aggressive therapy in subjects with metabolic syndrome will result in a future decrease in cardiovascular morbidity and mortality worldwide.

Key words

metabolic syndrome cardiovascular risk cardiometabolic risk hypertension cardiovascular prevention 


  1. 1.
    Eckel RH, Kahn R, Robertson RM, et al. Preventing cardiovascular disease and diabetes. Diabetes Care 2006; 29: 1697–9PubMedCrossRefGoogle Scholar
  2. 2.
    Despres JP, Lemieux I. Abdominal obesity and metabolic syndrome. Nature 2006; 444: 881–7PubMedCrossRefGoogle Scholar
  3. 3.
    National Cholesterol Education Program. Third Report of the National Cholesterol Education Program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel III): final report. Circulation 2002; 106: 3143–421Google Scholar
  4. 4.
    Grundy SM, Cleeman JI, Daniels SR, et al. Diagnosis and management of the metabolic syndrome: an American Heart Association/National Heart, Lung, and Blood Institute Scientific Statement. Circulation 2005; 112: 2735–52PubMedCrossRefGoogle Scholar
  5. 5.
    Alberti KG, Zimmet P, Shaw J. Metabolic syndrome: a new world-wide definition: a Consensus Statement from the International Diabetes Federation. Diabet Med 2006; 23: 469–80PubMedCrossRefGoogle Scholar
  6. 6.
    de la Sierra A, Romero R, Bonet J, et al. Prevalence and general features of the metabolic syndrome in the Spanish hypertensive population. Med Clin (Barc) 2006; 126: 406–9CrossRefGoogle Scholar
  7. 7.
    The Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). 2007 Guidelines for the management of arterial hypertension. J Hypertens 2007; 25: 1105–87Google Scholar
  8. 8.
    Galassi A, Reynolds K, He J. Metabolic syndrome and risk of cardiovascular disease: a meta-analysis. Am J Med 2006; 119: 812–9PubMedCrossRefGoogle Scholar
  9. 9.
    Schillaci G, Pirro M, Vaudo G, et al. Prognostic value of the metabolic syndrome in essential hypertension. J Am Coll Cardiol 2004; 43: 1817–22PubMedCrossRefGoogle Scholar
  10. 10.
    Ford ES. Risks for all-cause mortality, cardiovascular disease, and diabetes associated with the metabolic syndrome: a summary of the evidence. Diabetes Care 2005; 28: 1769–78PubMedCrossRefGoogle Scholar
  11. 11.
    Kurella M, Lo JC, Chertow GM. Metabolic syndrome and the risk for chronic kidney disease among nondiabetic adults. J Am Soc Nephrol 2005; 16: 2134–40PubMedCrossRefGoogle Scholar
  12. 12.
    Samuelsson O, Pennert K, Andersson O, et al. Diabetes mellitus and raised serum triglyceride concentration in treated hypertension: are they of prognostic importance: observational study. BMJ 1996; 314: 660–3CrossRefGoogle Scholar
  13. 13.
    Verdecchia P, Reboldi G, Angeli F, et al. Adverse prognostic significance of new diabetes in treated hypertensive subjects. Hypertension 2004; 43: 963–9PubMedCrossRefGoogle Scholar
  14. 14.
    Elliott WJ, Meyer PM. Incident diabetes in clinical trials of antihypertensive drugs: a network meta-analysis. Lancet 2007; 369: 201–7PubMedCrossRefGoogle Scholar
  15. 15.
    Kostis JB, Wilson AC, Freudenberger RS, et al. Long-term effect of diuretic-based therapy on fatal outcomes in subjects with isolated systolic hypertension with and without diabetes. Am J Cardiol 2005; 95: 29–35PubMedCrossRefGoogle Scholar
  16. 16.
    Barzilay JI, Davis BR, Cutler JA, et al. Fasting glucose levels and incident diabetes mellitus in older nondiabetic adults randomized to receive 3 different classes of antihypertensive treatment: a report from the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). Arch Intern Med 2006; 166: 2191–201PubMedCrossRefGoogle Scholar
  17. 17.
    Alderman MH, Cohen H, Madhavan S. Diabetes and cardiovascular events in hypertensive patients. Hypertension 1999; 33: 1130–4PubMedCrossRefGoogle Scholar
  18. 18.
    Klein S, Burke LE, Bray GA, et al. Clinical implications of obesity with specific focus on cardiovascular disease: a statement for professionals from the American Heart Association Council on Nutrition, Physical Activity, and Metabolism: endorsed by the American College of Cardiology Foundation. Circulation 2004; 110: 2952–67PubMedCrossRefGoogle Scholar
  19. 19.
    Knowler WC, Barrett-Connor E, Fowler SE, et al. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N Engl J Med 2002; 346: 393–403PubMedCrossRefGoogle Scholar
  20. 20.
    Cook NR, Cutler JA, Obarzanek E, et al. Long term effects of dietary sodium reduction on cardiovascular disease outcomes: observational follow-up of the trials of hypertension prevention (TOHP). BMJ 2007; 334: 885PubMedCrossRefGoogle Scholar
  21. 21.
    Sacks FM, Svetkey LP, Vollmer WM, et al. Effects on blood pressure of reduced dietary sodium and the Dietary Approaches to Stop Hypertension (DASH) diet. DASH-Sodium Collaborative Research Group. N Engl J Med 2001; 344: 3–10PubMedCrossRefGoogle Scholar
  22. 22.
    Knoops KT, de Groot LC, Kromhout D, et al. Mediterranean diet, lifestyle factors, and 10-year mortality in elderly European men and women: the HALE project. JAMA 2004; 292: 1433–9PubMedCrossRefGoogle Scholar
  23. 23.
    de la Sierra A, Ruilope LM. Management of cardiovascular risk factors in patients with metabolic syndrome. Cardiovasc Hematol Agents Med Chem 2007; 5: 209–14PubMedCrossRefGoogle Scholar
  24. 24.
    Chobanian AV, Bakris GL, Black HR, et al. Seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. Hypertension 2003; 42: 1206–52PubMedCrossRefGoogle Scholar
  25. 25.
    Schupp M, Janke J, Clasen R, et al. Angiotensin type 1 receptor blockers induce peroxisome proliferator-activated receptor-gamma activity. Circulation 2004; 109: 2054–7PubMedCrossRefGoogle Scholar
  26. 26.
    The ONTARGET Investigators. Telmisartan, ramipril, or both in patients at high risk for vascular events. N Engl J Med 2008; 358: 1547–59Google Scholar
  27. 27.
    Vasan RS, Larson MG, Leip EP, et al. Impact of high-normal blood pressure on the risk of cardiovascular disease. N Engl J Med 2001; 345: 1291–7PubMedCrossRefGoogle Scholar
  28. 28.
    Vasan RS, Larson MG, Leip EP, et al. Assessment of frequency of progression to hypertension in non-hypertensive participants in the Framingham Heart Study: a cohort study. Lancet 2001; 358: 1682–6PubMedCrossRefGoogle Scholar
  29. 29.
    Julius S, Nesbitt SD, Egan BM, et al. Feasibility of treating prehypertension with an angiotensin-receptor blocker. N Engl J Med 2006; 354: 1685–97PubMedCrossRefGoogle Scholar
  30. 30.
    Sever PS, Dahlof B, Poulter NR, et al. Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-thanaverage cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial-Lipid Lowering Arm (ASCOT-LLA): a multicentre randomised controlled trial. Lancet 2003; 361: 1149–58PubMedCrossRefGoogle Scholar
  31. 31.
    Canner PL, Furberg CD, McGovern ME. Benefits of niacin in patients with versus without the metabolic syndrome and healed myocardial infarction (from the Coronary Drug Project). Am J Cardiol 2006; 97: 477–9PubMedCrossRefGoogle Scholar
  32. 32.
    Tenenbaum A, Motro M, Fisman EZ, et al. Bezafibrate for the secondary prevention of myocardial infarction in patients with metabolic syndrome. Arch Intern Med 2005; 165: 1154–60PubMedCrossRefGoogle Scholar
  33. 33.
    Nissen SE, Tardif JC, Nicholls SJ, et al. Effect of torcetrapib on the progression of coronary atherosclerosis. N Engl J Med 2007; 356: 1304–16PubMedCrossRefGoogle Scholar
  34. 34.
    Chiasson JL, Josse RG, Gomis R, et al. Acarbose for prevention of type 2 diabetes mellitus: the STOP-NIDDM randomised trial. Lancet 2002; 359: 2072–7PubMedCrossRefGoogle Scholar
  35. 35.
    The DREAM (Diabetes Reduction Assessment with ramipril and rosiglitazone Medication) Trial Investigators. Effect of rosiglitazone on the frequency of diabetes in patients with impaired glucose tolerance or impaired fasting glucose: a randomised controlled trial. Lancet 2006; 368: 1096–105Google Scholar
  36. 36.
    Nissen SE, Wolski K. Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes. N Engl J Med 2007; 356: 2457–71PubMedCrossRefGoogle Scholar
  37. 37.
    Arterburn DE, Crane PK, Veenstra DL. The efficacy and safety of sibutramine for weight loss: a systematic review. Arch Intern Med 2004; 164: 994–1003PubMedCrossRefGoogle Scholar
  38. 38.
    Scholze J, Grimm E, Hermann D, et al. Optimal treatment of obesity-related hypertension: the Hypertension-Obesity-Sibutramine (HOS) study. Circulation 2007; 115: 1991–8PubMedCrossRefGoogle Scholar
  39. 39.
    Hutton B, Fergusson D. Changes in body weight and serum lipid profile in obese patients treated with orlistat in addition to a hypocaloric diet: a systematic review of randomized clinical trials. Am J Clin Nutr 2004; 80: 1461–8PubMedGoogle Scholar
  40. 40.
    Van Gaal LF, Rissanen AM, Scheen AJ, et al. Effects of the cannabinoid-1 receptor blocker rimonabant on weight reduction and cardiovascular risk factors in overweight patients: 1-year experience from the RIO-Europe study. Lancet 2005; 365: 1389–97PubMedCrossRefGoogle Scholar
  41. 41.
    Pi-Sunyer FX, Aronne LJ, Heshmati HM, et al. Effect of rimonabant, a cannabinoid-1 receptor blocker, on weight and cardiometabolic risk factors in overweight or obese patients: RIO-North America: a randomized controlled trial. JAMA 2006; 295: 761–75PubMedCrossRefGoogle Scholar
  42. 42.
    Despres JP, Golay A, Sjostrom L. Effects of rimonabant on metabolic risk factors in overweight patients with dyslipidemia. N Engl J Med 2005; 353: 2121–34PubMedCrossRefGoogle Scholar
  43. 43.
    Scheen AJ, Finer N, Hollander P, et al. Efficacy and tolerability of rimonabant in overweight or obese patients with type 2 diabetes: a randomised controlled study. Lancet 2006; 368: 1660–72PubMedCrossRefGoogle Scholar
  44. 44.
    Nissen SE, Nichols SJ, Wolski K, et al. Effect of rimonabant on progression of atherosclerosis in patients with abdominal obesity and coronary artery disease: the STRADIVARIUS randomized controlled trial. JAMA 2008; 299: 1547–60PubMedCrossRefGoogle Scholar
  45. 45.
    Gaede P, Vedel P, Larsen N, et al. Multifactorial intervention and cardiovascular disease in patients with type 2 diabetes. N Engl J Med 2003; 348: 383–93PubMedCrossRefGoogle Scholar
  46. 46.
    Antithrombotic Trialists’ Collaboration. Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients. BMJ 2002; 324: 71–86Google Scholar

Copyright information

© Adis Data Information BV 2008

Authors and Affiliations

  1. 1.Hypertension Unit, Department of Internal Medicine, Hospital ClinicUniversity of BarcelonaBarcelonaSpain

Personalised recommendations